---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-069317"
form_type: "8-K"
ticker: "RIGL"
cik: "0001034842"
company_name: "RIGEL PHARMACEUTICALS INC"
filed_at: "2022-06-08T23:59:59+00:00"
generated_at: "2026-06-25T03:25:19.971935+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Rigel FORWARD Phase 3 trial of fostamatinib in wAIHA misses primary endpoint overall; positive regional signals seen

## Summary
- Primary endpoint of durable hemoglobin response not met: fostamatinib 35.6% vs placebo 26.7% (p=0.398).
- Post-hoc analysis: U.S./Canada/Australia/Western Europe showed significant benefit (36.0% vs 10.7%, p=0.03); Eastern Europe did not (35% vs 52.9%, p=0.304).
- Safety profile consistent with prior data; most common AEs: diarrhea (26.7%), hypertension (24.4%), fatigue (15.6%).
- Rigel plans further data analysis and discussion with FDA regarding regional differences.
- 71 of 90 patients (79%) enrolled in open-label extension study; data to be reported later.

## SEC filing metadata
- accession: 0001104659-22-069317
- form_type: 8-K
- ticker: RIGL
- cik: 0001034842
- company_name: RIGEL PHARMACEUTICALS INC
- filed_at: 2022-06-08T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1034842/000110465922069317/0001104659-22-069317-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1034842/000110465922069317/tm2217976d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-069317
- JSON: https://secwatch.observer/filing/0001104659-22-069317.json
- Plain text: https://secwatch.observer/filing/0001104659-22-069317.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.